Moderna Announces Chief Legal Officer Departure
Moderna, Inc. entered into a retirement agreement with its chief legal officer, Shannon Thyme Klinger, whose employment will end on March 31, 2027. Under the agreement, the company will pay her $1,628,300 in severance over 12 months following her departure.
Key points
- According to the document, Shannon Thyme Klinger will remain in her role until March 31, 2027, transitioning duties as requested by the company.
- The litigation-related payments for the departing officer are not guaranteed.
Retirement Agreement Terms
According to the document, Shannon Thyme Klinger will remain in her role until March 31, 2027, transitioning duties as requested by the company. The $1,628,300 severance payment represents her annual base salary and target annual bonus.
The agreement also includes performance-based litigation payments. Klinger may receive $2.5 million if Moderna prevails in disputes with Arbutus Biopharma Corporation and Genevant Sciences, and up to $5.5 million depending on the outcome of cases against Pfizer, Inc. and BioNTech SE.
In its third-quarter 2026 report for the period ending September 30, Moderna reported improved financial results compared to the prior year. The company posted revenue of $1,313 million and net income of $162 million, compared to revenue of $1,016 million and a net loss of $200 million in the third quarter of 2025.
What It Means for Shareholders
The litigation-related payments for the departing officer are not guaranteed. The company will only make these payments if it prevails in the relevant disputes.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Moderna
A notification in your browser or on your phone when we publish about Moderna. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
